Overview and Scope
Kidney cancer diagnostics and therapeutics refer to a process of methods and treatments used for diagnosing and managing kidney cancer, also known as renal cell carcinoma. These approaches aim to detect the presence of kidney cancer, determine its stage and extent, and provide appropriate treatment options to manage the disease.
Sizing and Forecast
The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements.
The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-diagnostics-and-therapeutics-global-market-report
Segmentation & Regional Insights
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma, Other Cancer Types
2) By Component: Drugs, Diagnostics
3) By Diagnostics: Biopsy, CT Scan, Nephro-ureteroscopy, Intravenous Pyelogram, Ultrasound
4) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy
5) By End-Users: Hospitals, Pharmaceutical Labs, Genomics Laboratories
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of kidney cancer is expected to drive the growth of kidney cancer diagnostics and therapeutics market. Kidney cancer refers to a condition that originates when the normal cells in one or both kidneys undergo abnormal changes and exhibit uncontrolled growth, resulting in the formation of a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer play a crucial role in the management and treatment of the disease, offering several benefits for patients. offer several benefits in the management of kidney cancer, such as early detection, accurate diagnosis, treatment selection, personalized medicine, and treatment monitoring. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization working for cancer care, in the United States, kidney cancer will be discovered in 81,800 individuals in 2023 (52,360 males and 29,440 women). And in 2020, kidney cancer will have affected 431,288 individuals globally. Therefore, the increasing prevalence of kidney cancer is expected to propel the growth of kidney cancer diagnostics and therapeutics market.
Key Industry Players
Major companies operating in the kidney cancer diagnostics and therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited
The kidney cancer diagnostics and therapeutics market report table of contents includes:
1. Executive Summary
2. Kidney Cancer Diagnostics And Therapeutics Market Characteristics
3. Kidney Cancer Diagnostics And Therapeutics Market Trends And Strategies
4. Kidney Cancer Diagnostics And Therapeutics Market – Macro Economic Scenario
5. Global Kidney Cancer Diagnostics And Therapeutics Market Size and Growth
.
.
.
32. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Benchmarking
33. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market
35. Kidney Cancer Diagnostics And Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
